211 related articles for article (PubMed ID: 19844712)
1. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
[TBL] [Abstract][Full Text] [Related]
2. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
4. Hypoalbuminemia in patients with multiple myeloma.
Chen YH; Magalhaes MC
Arch Intern Med; 1990 Mar; 150(3):605-10. PubMed ID: 2310279
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
7. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
8. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
9. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Sánchez-Cortes E; García-Chávez J; Montiel-Cervantes L; Reyes-Maldonado E; Majluf-Cruz A; Mayani H
Ann Hematol; 2009 Jan; 88(1):59-66. PubMed ID: 18648809
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
14. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
18. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
[TBL] [Abstract][Full Text] [Related]
19. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
20. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]